• 作者：Marisa Cañ ; adas Garre^a ; ^{marisacgarre@gmail.com} ; Mart&#237 ; n Ló ; pez de la Torre Casares^b ; Patricia Becerra Massare^c ; Miguel Á ; ngel Ló ; pez Nevot^d ; Jesú ; s Villar Del Moral^e ; Nuria Muñ ; oz Pé ; rez^e ; Ricardo V&#237 ; lchez Joya^b ; Rosa Montes Ram&#237 ; rez^f ; José ; Manuel Llamas Elvira^a
• 关键词：Mutació ; n BRAFT1799A ; Carcinoma papilar de tiroides ; Recidiva tumoral
• 刊名：Endocrinolog铆a y Nutrici贸n
• 出版年：2011
• 期刊代码：pca151_15750922
• 类别：med
• 出版时间：April 2011
• 卷：58
• 期：4
• 页码：175-184
• 文件大小：157 K

Background and objective

The BRAF^T1799A mutation is reported to be associated to aggressive, persistent, and recurrent tumor in papillary thyroid carcinoma (PTC) patients. Association of the BRAF^T1799A mutation in the primary tumor with the clinicopathological characteristics of PTC patients was analyzed.

Patients, material and methods

Ninety-seven PTC patients were followed up for a median of 64.1 months. The BRAF^T1799A mutation was analyzed in DNA from initial thyroidectomy biopsies by PCR amplification and restriction fragment length polymorphism using TspRI enzyme. Positive cases were confirmed by DNA sequencing. Statistical association between BRAF^T1799A mutation and clinicopathological characteristics was analyzed by the relevant hypothesis tests and logistic regression.

Results

46.4%of patients were positive for the BRAF^T1799A mutation. Bivariate and multivariate analysis showed the BRAF^T1799A mutation to be only associated to age over 60 years (odds ratio [OR] = 5.5; 95%confidence interval [CI],1.4-21.9; p = 0.019) and to tumor size of 1 cm or greater (OR = 3.6, 95%CI, 1.2-10.3; p = 0.016). The BRAF^T1799A mutation was not associated to histological subtype, metastasis, recurrence, more aggressive treatments (ablative I¹³¹ therapy or surgery), or PTC persistence at the end of follow-up.

Conclusions

The BRAFT1799A mutation is associated to age over 60 and a tumor size of 1 cm or greater, but not to other clinicopathological characteristics, tumor recurrence or PTC persistence.